StreetAlpha.app
Home › Stocks › GNLX

GENELUX Corp (GNLX)

Healthcare
$2.00
▲ +4.17%
LAST CLOSE · NOV 17

Genelux develops cancer immunotherapies based on a modified vaccinia virus that infects and destroys tumor cells. It last closed at $2.00 on Nov 17, up 4.17% on the day.

AI Auto Pilots
Is GNLX in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$8K
+0.0% vs a year ago
Net income
−$32.1M
−401812.5% margin
EPS (diluted)
−$0.86
Free cash flow
−$26.4M
−329575.0% margin
Valuation
Market cap
$96.1M
48.1M shares
P/E
–
No P/E while losing money
Price to sales
12016.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.4M
At Sep 30
Shareholder equity
$9.2M
Shares outstanding
48.1M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $11.1M$11.1MFY2022FY2023: $170K$170KFY2023FY2024: $8K$8KFY2024FY2025: $8K$8KFY2025

From GNLX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated GNLX in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 400.0% upside

Based on 1 analyst who set a price target on GNLX in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $2.00.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $2.00
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
Roth MKMInitiated
Sep 25Buy$10
DateFirmActionRatingPrice target
Sep 25Roth MKMInitiatedBuy$10
Loading…

Technical Analysis

GNLX · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 32% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $1.98, and the nearest resistance the Pivot R1 at $2.07.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.4%/day
Key levels
$5.8952 week high+194.5%
$2.64200 day average+32.0%
$2.55100 day average+27.5%
$2.2950 day average+14.5%
$2.09Swing high (Nov 9)+4.5%
$2.07Pivot R1+3.5%
$2.00Last close
$1.9820 day average−1.0%
$1.96Pivot−2.0%
$1.89Pivot S1−5.5%
$1.86Swing low (Oct 27)−7.0%
$1.7752 week low−11.5%
Indicators
RSI (14)45.82Middle of its rangeNeutral
MACD-0.11Above its signal lineBullish
Stochastic31.0Middle of its rangeNeutral
ADX (14)14.7No clear trend
Williams %R-54.5Oversold below −80, overbought above −20Neutral
CCI (20)-34.1Oversold below −100, overbought above 100Neutral
Rate of change+4.2%Change over 10 sessionsBullish
ATR (14)$0.17Typical daily range, 8.4% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for GNLX

What happened before

See how GNLX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GNLX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GNLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GNLX in the last 90 days.

Loading…

See today’s whale options flow across the market →

GNLX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲30 buying vs 22 selling
  • ▲Held by funds +0.9 pts
  • ▲Funds holding +6
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7872+8.3%
In funds' top 10110.0%
Held by funds21.3%20.4%+0.9 pts
New / increased14 / 1610 / 18+7.1%
Reduced / sold out14 / 815 / 10−12.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GNLX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GNLX is in one of them and how their past GNLX trades turned out.

GNLX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GNLX in an article yet. Here's the latest on the wider market.

About GENELUX

Genelux is a biopharmaceutical company based in Westlake Village, California, that develops cancer treatments built on a modified vaccinia virus. Its lead candidate, Olvi-Vec, is designed to infect and destroy tumor cells while prompting the immune system to attack cancer throughout the body. The company is testing it in ovarian cancer, lung cancer and small cell lung cancer, aiming at patients whose tumors have responded poorly to standard treatments such as chemotherapy. It also operates a manufacturing facility in San Diego and has licensed rights to Olvi-Vec in China to a partner.

Headquarters
Westlake Village, CA